Premium
Current application of National Institute for Health and Clinical Excellence (NICE) guidance in the management of patients with severe psoriasis: a clinical audit against NICE guidance in seven National Health Service specialist dermatology units in England
Author(s) -
Bewley A.,
Cerio R.,
Clement M.,
Hunt S.,
Lucke T.,
Ratnavel R.,
Walton S.,
Percival F.
Publication year - 2011
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2010.04011.x
Subject(s) - nice , excellence , medicine , audit , service (business) , psoriasis , national service , family medicine , nursing , business , political science , accounting , dermatology , computer science , law , programming language , marketing
Summary Background. Psoriasis affects 1–2% of the UK population, with 20–30% of those affected having severe psoriasis managed with systemic therapies. Biological agents are a useful option when other systemic therapies have failed. The National Institute for Health and Clinical Excellence (NICE) in the UK has published three sets of guidance relating to the use of biological agents. Aim. To establish whether biological agents were being used in line with NICE guidance. Methods. The study was conducted in seven specialist dermatology units, and involved the retrospective collection of data from patients treated with biological agents since the introduction of the NICE guidance. Results. In total, 176 patients with 212 episodes of treatment were included in the study. Biologics were started for appropriately severe disease in 85% of cases ( n = 180) and only after failure, intolerance or contraindication to standard systemic therapies in 97% of cases ( n = 206). Etanercept was discontinued appropriately in responders before week 24 in only 12% (five of 60 responders). Across all agents, 40% (72 of 178 with continuity status) were continued on treatment despite not achieving an adequate response according to NICE criteria. Conclusions. In the seven sites audited, compliance with national guidance was entirely appropriate in terms of therapy initiation; however, the requirement to discontinue etanercept in responders was rarely followed. Similarly, discontinuation of biologicals in nonresponders was not routine practice. This may indicate a reluctance of both patients and clinicians to withdraw an at least partly effective therapy from these refractory patients.